Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: results from a questionnaire conducted in switzerland, austria, and belgium

HIGHLIGHTS

• who: Alicia Rovu00f3 and colleagues from the Department of Haematology and Central Haematology Laboratory, Bern University Cantonal Hospital, Muu0308nsterlingen, Switzerland have published the paper: Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium, in the Journal: PLOS ONE of April/21,/2022
• what: In line with this, studies have demonstrated that patients with ITP have worse HRQoL than age- and sexmatched comparisons or the general population, and comparable HRQoL to patients with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.